Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRégis Peffault de LatourÉFÉdouard ForcadeEAEmanuele Angelucci

Discussion

Loading...

Member takes

Overview

Registry-based study shows alloHSCT improves progression-free survival in relapsed NLPHL, suggesting new treatment approaches.

Key Points

  • Evaluate outcomes of allogeneic stem cell transplantation in relapsed or refractory nodular lymphocyte-predominant Hodgkin lymphoma.
  • Included adults with NLPHL receiving alloHSCT from EBMT registry.
  • Primary endpoint was 5-year progression-free survival post-alloHSCT.
  • Analyzed variables like age, sex, disease status, and donor type.
  • Five-year progression-free survival rate was 46.7%.
  • Overall survival at five years was 63.0%.
  • Disease status at transplant significantly affected progression-free survival.

Cite This Study

Latour et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d066https://doi.org/10.1182/blood-2025-1842
View Full Paper
Ask AI
Bookmark
Share